Asterand Announces Collaborative Agreement to Characterize Antibodies
News Apr 24, 2009
Asterand plc has announces that it has entered into a collaborative agreement with Abcam plc. Asterand will undertake the validation and characterization of a selected group of Abcam antibodies for immuno-histochemistry applications using Asterand’s PhaseZERO® Human Tissue Services platform.
Through this agreement, Asterand will utilize its proprietary Target Evaluator™ database to pinpoint the expression patterns of selected antibody targets across a panel of human tissue types. The database consists of quantitative human gene expression profiles that chart the expression topography of more than 2,000 commercially relevant gene transcripts across a panel of 72 human tissues.
Once appropriate tissue has been selected for testing, Asterand will validate the Abcam antibodies using immuno-histochemical detection to determine the optimal dilutions and concentrations of the antibodies for use with human tissue. The resulting data and photomicrographs will be incorporated into Abcam’s literature and technical support documentation for each antibody tested.
All services provided through this agreement are part of Asterand’s standard PhaseZERO® human tissue services platform. The tested antibodies will be sold through Abcam’s online catalogue. Terms of the agreement were not disclosed.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.